Dihydroartemisinin protects blood–brain barrier permeability during sepsis by inhibiting the transcription factor <scp>SNAI1</scp>

Fuhong Liu, Jing Liu, Jing Liu, Hongjie Xiang, Zongguo Sun, Yan Li, Xiao Li, Yanjun Liu, Ju Liu, Ju Liu

Clinical and Experimental Pharmacology and Physiology · 2022 · 10 citations · 39 references

DOIFull text

Open access

Concepts

Abstract

Blood-brain barrier (BBB) injury is involved in the pathogenesis of sepsis-associated encephalopathy. In this study, we used dihydroartemisinin (DHA), a derivative of artemisinin, to treat a cecal ligation and puncture (CLP)-induced mouse sepsis model and a tumour necrosis factor α (TNF-α)-stimulated human cerebral microvessel endothelial cells (hCMEC)/D3 cell line. We found that DHA decreased BBB permeability and increased the expression of the tight junction protein occludin (OCLN) in the CLP model. In hCMEC/D3 cells, DHA decreased TNF-α-induced hyperpermeability and increased the expression of OCLN. DHA also repressed SNAI1 expression in the CLP mouse model and in TNF-α-stimulated hCMEC/D3 cells. These data suggest that DHA protects BBB permeability during sepsis by stimulating the expression of OCLN, by downregulating the expression of the SNAI1 transcription factor.

References

39